Trials / Terminated
TerminatedNCT03896945
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | oral capsules |
| DRUG | AVP-786 | oral capsules |
Timeline
- Start date
- 2019-02-15
- Primary completion
- 2023-05-23
- Completion
- 2023-05-23
- First posted
- 2019-04-01
- Last updated
- 2024-05-24
Locations
72 sites across 4 countries: United States, Bulgaria, Poland, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03896945. Inclusion in this directory is not an endorsement.